Mendus AB (publ) (IMMU.ST)
Develops cancer-fighting immune cell therapies for blood cancers like leukemia.
6.89+0.00%Healthcare
StockGlow Score
Bullish
BearishBullish
1 year ago-27.2%
The outlook
Mendus AB trades at 6.89 with strong analyst backing—averaging 1.5 out of 2 on a buy scale—and sits above both its 50- and 200-day moving averages. The stock is positioned midway in its 52-week range, while the average analyst price target sits approximately 379% above the current price.
What’s behind the score
Analyst consensusStrong Buy — 1.5 avg of 2 analysts
Price trendAbove its 50- & 200-day averages
52-week range49% of the way from its 52-week low to high
Price targetAvg target +379% vs current price
Analyst price target
~12-month · 2 analysts33.00average target+379.0% vs now
Now 6.89
Low 16.00High 50.00
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
$422.2M
52-wk high
10.02
52-wk low
3.86
50-day avg
5.96
200-day avg
5.42
Trailing P/E
—